53673-39-5

Usage

Uses

Used in Pharmaceutical Applications:
1-(2-aminoethyl)-3-ethylurea hydrochloride is used as a therapeutic agent for the treatment of various medical conditions, including cancer. Its application in this context is attributed to its potential to be converted into an active drug within the body, offering a promising avenue for the development of novel treatment strategies.
Used in Research Studies:
In the field of research, 1-(2-aminoethyl)-3-ethylurea hydrochloride is employed as a chemical reagent, facilitating the exploration of its properties and potential applications. Its use in this capacity aids in the advancement of knowledge within the medical and pharmaceutical sectors.
Used in Drug Development:
1-(2-aminoethyl)-3-ethylurea hydrochloride is also utilized in the development of new pharmaceutical compounds. Its unique chemical structure and potential medicinal properties make it a valuable asset in the creation of innovative and effective drugs.
Used in Medical Applications:
1-(2-aminoethyl)-3-ethylurea hydrochloride is used as a prodrug, which is a compound that is converted into an active drug within the body. This application is significant as it allows for the development of treatments that can be more easily administered and absorbed, potentially leading to improved patient outcomes.

Relevant academic research and scientific papers

Synthesis, structural characterization, and catalytic evaluation of phosphinoferrocene ligands bearing extended urea-amide substituents

New phosphinoferrocene ligands bearing extended polar amidourea pendants with the general formula Ph2PfcCONHCH2CH 2NHCONR2 (1; R2 = H2 (b), H/Et (c), Me2 (d), H/Ph (e)) and their model bis-amide Ph 2PfcCONHCH2CH2NHCOCH3 (1a) were prepared in good yields by amidation of 1′-(diphenylphosphino)ferrocene-1- carboxylic acid (Hdpf) with the appropriate amines in the presence of peptide coupling reagents. These ferrocene-based phosphinoureas were further employed as ligands in palladium(II) complexes with η3-allyl and NC-chelating supporting ligands: viz., [PdCl(η3-C 3H5)(1-κP)] (5a-e) and [PdCl(LNC)(1- κP)] (6a-e; LNC = [2-(dimethylamino-κN)methyl]phenyl- κC1). Both the free ligands and their Pd(II) complexes were characterized by spectroscopic methods (multinuclear NMR, IR, and MS) and by elemental analysis. The molecular structures of 1b·CH3OH, 1c, 5b,c, 6a, and two additional model complexes, [PdCl(η3-C 3H5)(Hdpf-κP)] (5f) and [PdCl(η3- C3H5)(Ph2PfcCONH2-κP)] (5g), were determined by single-crystal X-ray diffraction analysis. All Pd(II) complexes were evaluated as catalysts in the cross-coupling of boronic acids and acyl halides to give ketones in a toluene/water biphasic mixture. Extensive reaction studies with compound 5e, which not only exerts good catalytic activity but is also readily accessible in a defined crystalline form, demonstrated efficient coupling reactivity for unsaturated substrates such as (substituted) benzeneboronic acids and benzoyl chlorides. The results also revealed that reaction difficulties encountered with less reactive substrates (e.g., insoluble aromatic boronic acids and all saturated aliphatic boronic acids) can be avoided by properly selecting the reaction partners, for example through transposition of substituents between reaction partners. Three representative benzophenones (4-fluoro-, 4-nitro-, and 4,4′-dinitrobenzophenone) were structurally characterized by single-crystal X-ray crystallography.